BioStock: PHI’s CEO comments on the approved US listing

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
Read the full interview with Patrik Eschricht on biostock.se.
Further reading

BioStock: Altium fuels PHI’s forward drive
BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore the current pivotal developments and their impact on PHI’s trajectory.

BioStock: PHI links up with two regenerative medicine networks
BioStock contacted CEO Patrik Eschricht to learn more about the company’s future strategies in regenerative medicine and the pivot toward the clinical market.

BioStock: PHI charts a bold course to impact regenerative medicine
BioStock contacted CEO Patrik Eschricht to delve into the year-end report’s highlights and shed light on the company’s vision and initiatives.

BioStock: The five best life science stocks of the first half-year
PHI is proud to be highlighted as one of the top 5 best-performing Swedish life science stocks in the first half of 2023.